Sign In
Buy BHVN
$13.50
-0.320 (-2.32%)
At Close: Jul 31, 2026
Biohaven Announces Proposed Public Offering of Common Shares
04:05pm, Wednesday, 17'th Apr 2024
NEW HAVEN, Conn. , April 17, 2024 /PRNewswire/ -- Biohaven Ltd.
Biohaven's first-in-class Molecular Degrader of Extracellular Proteins (MoDE™) technology targeting IgG removal, BHV-1300, was selected for an oral presentation at AAN highlighting its novel mechani
How Biohaven's experimental obesity drug could prevent muscle loss
06:19pm, Monday, 25'th Mar 2024
Vlad Coric, Biohaven CEO, joins 'Fast Money' to discuss the weight loss drug wars and the company's experimental obesity drug.
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
04:05pm, Thursday, 29'th Feb 2024
Driving clinical, regulatory, and operational excellence across five innovative platforms focused on immunology, neuroscience, and oncology: Portfolio targeting large indications including obesity, ep
Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)
12:48pm, Wednesday, 28'th Feb 2024
Biohaven's stock rose 130% post "Sell" recommendation; overlooked assets like BHV-7000 suggest early growth stages remain. The company's pipeline, particularly their Kv7 activators and IgG degrader, s
Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs
05:31pm, Thursday, 25'th Jan 2024
Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies.
Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs
06:00am, Thursday, 25'th Jan 2024
Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies.
Five proprietary platforms fueling multiple clinical programs Targeting large indications including epilepsy, bipolar disorder, depression, obsessive-compulsive disorder, migraine, pain, obesity, Alzh
Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference
07:00am, Tuesday, 02'nd Jan 2024
NEW HAVEN, Conn. , Jan. 2, 2024 /PRNewswire/ -- Biohaven Ltd.
Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting
04:30pm, Friday, 01'st Dec 2023
Biohaven reported full results from the BHV-7000 Phase 1 study examining doses up to 120 mg daily, demonstrating BHV-7000 was well-tolerated at all doses studied without the typical central nervous sy
Is Biohaven Ltd. (BHVN) Outperforming Other Medical Stocks This Year?
11:17am, Thursday, 16'th Nov 2023
Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year.
Biohaven Ltd. (BHVN) Is a Great Choice for 'Trend' Investors, Here's Why
10:32am, Monday, 06'th Nov 2023
If you are looking for stocks that are well positioned to maintain their recent uptrend, Biohaven Ltd. (BHVN) could be a great choice.
Are Medical Stocks Lagging Biohaven Ltd. (BHVN) This Year?
11:21am, Tuesday, 31'st Oct 2023
Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year.
Here's Why Momentum in Biohaven Ltd. (BHVN) Should Keep going
10:33am, Thursday, 19'th Oct 2023
Biohaven Ltd. (BHVN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move.
Biohaven (BHVN) Up on Positive Data from Autoimmune Disease Drug
09:01am, Thursday, 28'th Sep 2023
Biohaven (BHVN) gains on preliminary data from a pre-clinical study on its pipeline candidate BHV-1300 targeting various autoimmune diseases.
